Genes and Cancer最新文献_第3页

Pathogenesis to management of hepatocellular carcinoma. 肝细胞癌的发病机制与治疗。

Genes and Cancer Pub Date : 2022-01-01 DOI: 10.18632/genesandcancer.226

Ben L Da, Kelly I Suchman, Lawrence Lau, Atoosa Rabiee, Aiwu Ruth He, Kirti Shetty, Herbert Yu, Linda L Wong, Richard L Amdur, James M Crawford, Sharon S Fox, Gregory M Grimaldi, Priya K Shah, Jonathan Weinstein, David Bernstein, Sanjaya K Satapathy, Nyasha Chambwe, Xiyan Xiang, Lopa Mishra

{"title":"Pathogenesis to management of hepatocellular carcinoma.","authors":"Ben L Da, Kelly I Suchman, Lawrence Lau, Atoosa Rabiee, Aiwu Ruth He, Kirti Shetty, Herbert Yu, Linda L Wong, Richard L Amdur, James M Crawford, Sharon S Fox, Gregory M Grimaldi, Priya K Shah, Jonathan Weinstein, David Bernstein, Sanjaya K Satapathy, Nyasha Chambwe, Xiyan Xiang, Lopa Mishra","doi":"10.18632/genesandcancer.226","DOIUrl":"https://doi.org/10.18632/genesandcancer.226","url":null,"abstract":"Hepatocellular carcinoma (HCC) is the most common primary liver cancer whose incidence continues to rise in many parts of the world due to a concomitant rise in many associated risk factors, such as alcohol use and obesity. Although early-stage HCC can be potentially curable through liver resection, liver-directed therapies, or transplantation, patients usually present with intermediate to advanced disease, which continues to be associated with a poor prognosis. This is because HCC is a cancer with significant complexities, including substantial clinical, histopathologic, and genomic heterogeneity. However, the scientific community has made a major effort to better characterize HCC in those aspects via utilizing tissue sampling and histological classification, whole genome sequencing, and developing viable animal models. These efforts ultimately aim to develop clinically relevant biomarkers and discover molecular targets for new therapies. For example, until recently, there was only one approved systemic therapy for advanced or metastatic HCC in the form of sorafenib. Through these efforts, several additional targeted therapies have gained approval in the United States, although much progress remains to be desired. This review will focus on the link between characterizing the pathogenesis of HCC with current and future HCC management.","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":"13 ","pages":"72-87"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

EZH2 suppresses endogenous retroviruses and an interferon response in cancers. EZH2在癌症中抑制内源性逆转录病毒和干扰素反应。

Genes and Cancer Pub Date : 2021-12-27 eCollection Date: 2021-01-01 DOI: 10.18632/genesandcancer.218

Panneerselvam Jayabal, Xiuye Ma, Yuzuru Shiio

{"title":"EZH2 suppresses endogenous retroviruses and an interferon response in cancers.","authors":"Panneerselvam Jayabal, Xiuye Ma, Yuzuru Shiio","doi":"10.18632/genesandcancer.218","DOIUrl":"https://doi.org/10.18632/genesandcancer.218","url":null,"abstract":"Ewing sarcoma is an aggressive cancer of bone and soft tissue in children. It is characterized by the chromosomal translocation between EWS and an Ets family transcription factor, most commonly FLI1. We recently reported that Ewing sarcoma depends on the autocrine signaling mediated by a cytokine, NELL2. NELL2 signaling stimulates the transcriptional output of EWS-FLI1 through the BAF chromatin remodeling complexes. While studying the impact of NELL2 silencing on Ewing sarcoma, we found that suppression of NELL2 signaling induces the expression of endogenous retroviruses (ERVs) and LINE-1 retrotransposons, an interferon response, and growth arrest. We determined that a histone methyltransferase, EZH2, is the critical downstream target of NELL2 signaling in suppressing ERVs, LINE-1, an interferon response, and growth arrest. We show that EZH2 inhibitors induce ERVs, LINE-1, and an interferon response in a variety of cancer types. These results uncover the role for NELL2-EZH2 signaling in suppressing endogenous virus-like agents and an antiviral response, and suggest the potential utility of EZH2 inhibitors in enhancing anti-tumor immunity.","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":" ","pages":"96-105"},"PeriodicalIF":0.0,"publicationDate":"2021-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39773647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Genomic profiling of DVL-1 and its nuclear role as a transcriptional regulator in triple negative breast cancer. DVL-1的基因组分析及其在三阴性乳腺癌中作为转录调节因子的核作用

Genes and Cancer Pub Date : 2021-10-13 eCollection Date: 2021-01-01 DOI: 10.18632/genesandcancer.217

Monica Sharma, Isabel Castro-Piedras, Austin Dwight Rodgers, Kevin Pruitt

{"title":"Genomic profiling of DVL-1 and its nuclear role as a transcriptional regulator in triple negative breast cancer.","authors":"Monica Sharma, Isabel Castro-Piedras, Austin Dwight Rodgers, Kevin Pruitt","doi":"10.18632/genesandcancer.217","DOIUrl":"https://doi.org/10.18632/genesandcancer.217","url":null,"abstract":"Dishevelled-1 (DVL-1) mediates Wnt signals critical for development and cellular homeostasis. DVL-1 is also linked with tumorigenesis, however its association with specific breast cancer (BC) subtypes and how it contributes to tumorigenicity remains poorly studied. Herein, using bioinformatics and genomics analyses, we investigate the role of DVL-1 in different molecular subtypes of BC. Our results demonstrate that DVL-1 is highly expressed in triple-negative BC compared to non-cancer tissues and associated with various clinical factors that may contribute to poor prognosis and survival rate. Another critical knowledge gap which remains poorly investigated involves the role of DVL-1 in the nucleus. While the cytoplasmic role of DVL-1 as a signaling hub has been extensively studied, the nuclear role of DVL-1 remains virtually unexplored. Herein for the first time, we have performed ChIP-Seq analyses to identify genomic regions targeted and regulated by DVL-1, thus highlighting its potential role as a regulator of transcription. Furthermore, we observed that DVL-1 peaks co-localize with H3K27me3 and EZH2, a repressive epigenetic mark and a histone methyltransferase respectively. Overall, our findings emphasize the importance of DVL-1 with TNBC-related pathology and identified unexpected gene targets of DVL-1, that may help explain the complexity of aberrant Wnt signaling in cancer.","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":" ","pages":"77-95"},"PeriodicalIF":0.0,"publicationDate":"2021-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39525855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Pairwise correlation of genes involved in glucose metabolism: a potential diagnostic marker of cancer? 参与糖代谢的基因的两两相关:癌症的潜在诊断标记?

Genes and Cancer Pub Date : 2021-06-17 eCollection Date: 2021-01-01 DOI: 10.18632/genesandcancer.216

Meena Kishore Sakharkar, Karthic Rajamanickam, Shaoping Ji, Sarinder Kaur Dhillon, Jian Yang

引用次数: 3

Value added by an inter-continental cancer consortium. 洲际癌症联盟的增值效应。

Genes and Cancer Pub Date : 2021-05-21 eCollection Date: 2021-01-01 DOI: 10.18632/genesandcancer.215

Mahadev Rao, Prasanna Venkatraman, Debabrata Mukhopadhyay, Susanta Roychoudhury, Nathan L Vanderford, Vivek M Rangnekar

引用次数: 0

Are molecular tests necessary to diagnose NIFTP? 诊断NIFTP需要分子检测吗?

Genes and Cancer Pub Date : 2021-03-15 eCollection Date: 2021-01-01 DOI: 10.18632/genesandcancer.213

Artur Kuchareczko, Janusz Kopczyński, Artur Kowalik, Kinga Hińcza, Agnieszka Płusa, Stanisław Góźdź, Aldona Kowalska

{"title":"Are molecular tests necessary to diagnose NIFTP?","authors":"Artur Kuchareczko, Janusz Kopczyński, Artur Kowalik, Kinga Hińcza, Agnieszka Płusa, Stanisław Góźdź, Aldona Kowalska","doi":"10.18632/genesandcancer.213","DOIUrl":"https://doi.org/10.18632/genesandcancer.213","url":null,"abstract":"In 2016, encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) was reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). In 2018 the criteria for NIFTP were widened by the inclusion of the complete lack of papillae. Secondary criteria, which include molecular examination, are helpful but not required for NIFTP diagnose. The aim of this study was to assess the molecular background of NIFTP and to answer the question if the aplication of revised criteria for NIFTP diagnosis is associated with the lack of oncogenic mutation. Repeat histopathological assessment of 1117 cases of papillary thyroid carcinoma (PTC) from 2000-2016 was conducted. Using initial (2016) and revised (2018) diagnostic criteria, NIFTP was diagnosed in 23 and 13 patients respectively. 50 tumor genes hotspots mutation analysis was conducted. BRAF V600E mutations were detected in patients who fulfilled only initial NIFTP criteria. Other high-risk mutations (TP53) were found in both groups of patients. The application of restrictive, revised diagnostic criteria for NIFTP negates the need for BRAF V600E examination, but these tumors still can harbor other high-risk oncogenic mutations nonetheless. Thus, molecular examination should be considered as a necessary step in NIFTP diagnostic process.","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":" ","pages":"39-50"},"PeriodicalIF":0.0,"publicationDate":"2021-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38895861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer. 在转移性her2阳性乳腺癌小鼠模型中，预防性颅脑照射可降低脑转移的发生率。

Genes and Cancer Pub Date : 2021-03-13 eCollection Date: 2021-01-01 DOI: 10.18632/genesandcancer.212

Daniel L Smith, Bisrat G Debeb, Parmeswaran Diagaradjane, Richard Larson, Swaminathan Kumar, Jing Ning, Lara Lacerda, Li Li, Wendy A Woodward

{"title":"Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer.","authors":"Daniel L Smith, Bisrat G Debeb, Parmeswaran Diagaradjane, Richard Larson, Swaminathan Kumar, Jing Ning, Lara Lacerda, Li Li, Wendy A Woodward","doi":"10.18632/genesandcancer.212","DOIUrl":"https://doi.org/10.18632/genesandcancer.212","url":null,"abstract":"Prophylactic cranial irradiation (PCI) can reduce the incidence of brain metastasis and improve overall survival in some patients with acute lymphoblastic leukemia or small-cell lung cancer. We examined the potential effects of PCI in a mouse model of breast cancer brain metastasis. The HER2+ inflammatory breast cancer cell line MDA-IBC3 was labeled with green fluorescent protein and injected via tail-vein into female SCID/Beige mice. Mice were then given 0 Gy or 4 Gy of whole-brain irradiation 2 days before tumor-cell injection or 5 days, 3 weeks, or 6 weeks after tumor-cell injection. Mice were sacrificed 4-weeks or 8-weeks after injection and brain tissues were examined for metastasis by fluorescent stereomicroscopy. In the unirradiated control group, brain metastases were present in 77% of mice at 4 weeks and in 90% of mice at 8 weeks; by comparison, rates for the group given PCI at 5 days after tumor-cell injection were 20% at 4 weeks (p=0.01) and 30% at 8 weeks (p=0.02). The PCI group also had fewer brain metastases per mouse at 4 weeks (p=0.03) and 8 weeks (p=0.006) versus the unirradiated control as well as a lower metastatic burden (p=0.01). Irradiation given either before tumor-cell injection or 3-6 weeks afterward had no significant effect on brain metastases compared to the unirradiated control. These results underscore the importance of timing for irradiating subclinical disease. Clinical whole brain strategies to target subclinical brain disease as safely as possible may warrant further study.","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":" ","pages":"28-38"},"PeriodicalIF":0.0,"publicationDate":"2021-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38895860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. 更正:CDK4/6抑制在临床前乳腺癌模型中为her2靶向治疗提供了强有力的辅助。

Genes and Cancer Pub Date : 2021-03-12 eCollection Date: 2021-01-01 DOI: 10.18632/genesandcancer.211

Agnieszka K Witkiewicz, Derek Cox, Erik S Knudsen

引用次数: 0

Key drug-targeting genes in pancreatic ductal adenocarcinoma. 胰腺导管腺癌的关键药物靶向基因。

Genes and Cancer Pub Date : 2021-03-11 eCollection Date: 2021-01-01 DOI: 10.18632/genesandcancer.210

Meena Kishore Sakharkar, Sarinder Kaur Dhillon, Mohit Mazumder, Jian Yang

{"title":"Key drug-targeting genes in pancreatic ductal adenocarcinoma.","authors":"Meena Kishore Sakharkar, Sarinder Kaur Dhillon, Mohit Mazumder, Jian Yang","doi":"10.18632/genesandcancer.210","DOIUrl":"https://doi.org/10.18632/genesandcancer.210","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal type of cancer. In this study, we undertook a pairwise comparison of gene expression pattern between tumor tissue and its matching adjacent normal tissue for 45 PDAC patients and identified 22 upregulated and 32 downregulated genes. PPI network revealed that fibronectin 1 and serpin peptidase inhibitor B5 were the most interconnected upregulated-nodes. Virtual screening identified bleomycin exhibited reasonably strong binding to both proteins. Effect of bleomycin on cell viability was examined against two PDAC cell lines, AsPC-1 and MIA PaCa-2. AsPC-1 did not respond to bleomycin, however, MIA PaCa-2 responded to bleomycin with an IC50 of 2.6 μM. This implicates that bleomycin could be repurposed for the treatment of PDAC, especially in combination with other chemotherapy agents. In vivo mouse xenograft studies and patient clinical trials are warranted to understand the functional mechanism of bleomycin towards PDAC and optimize its therapeutic efficacy. Furthermore, we will evaluate the antitumor activity of the other identified drugs in our future studies.","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":" ","pages":"12-24"},"PeriodicalIF":0.0,"publicationDate":"2021-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8045979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38895858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Gene signatures of cyclin-dependent kinases: a comparative study in naïve early and advanced stages of lung metastasis breast cancer among pre- and post-menopausal women. 周期蛋白依赖激酶的基因特征:绝经前和绝经后妇女早期和晚期肺癌转移naïve的比较研究。

Genes and Cancer Pub Date : 2021-02-10 eCollection Date: 2021-01-01 DOI: 10.18632/genesandcancer.209

Muhammad Fazal Hussain Qureshi, Muzna Shah, Mahira Lakhani, Zain Jawed Abubaker, Danish Mohammad, Hira Farhan, Iman Zia, Rida Tafveez, Samahir Tariq Khan, Ghani Rubina, Mushtaq Shamim, Haider Ghulam

{"title":"Gene signatures of cyclin-dependent kinases: a comparative study in naïve early and advanced stages of lung metastasis breast cancer among pre- and post-menopausal women.","authors":"Muhammad Fazal Hussain Qureshi, Muzna Shah, Mahira Lakhani, Zain Jawed Abubaker, Danish Mohammad, Hira Farhan, Iman Zia, Rida Tafveez, Samahir Tariq Khan, Ghani Rubina, Mushtaq Shamim, Haider Ghulam","doi":"10.18632/genesandcancer.209","DOIUrl":"https://doi.org/10.18632/genesandcancer.209","url":null,"abstract":"The Human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC) is a more aggressive tumor with 5 years median survival rates after metastasis. Despite successful treatment, unfortunately, the majority of affected patients die. Defects in cell cycle and transcription regulation phases which are governed by cyclin-dependent kinases (CDKs) are the hallmark of many cancers that underpinning the progression of the disease. Therefore, the current study looked at the alteration of six CDKs mRNA expression levels in pre- and postmenopausal lung metastasis BC groups; the majority were HER2+. Two hundred pre-and postmenopausal lung metastasis breast cancer and healthy control blood samples were taken for RNA isolation. Quantitative PCR was done for CDKs mRNA expressions. We observed overexpression of CDK11, CDK12, CDK17, CDK18, and CDK19 in both pre- and postmenopausal groups. However, CDK20 showed progressive downregulation from early to advanced stages in both groups of patients. Collectively, this data revealed that CDKs overexpression levels may predict BC disease progression and provide further rationale for novel anticancer strategies for HER2+ BC cancers.","PeriodicalId":38987,"journal":{"name":"Genes and Cancer","volume":" ","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38885859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1